NLM Digital Collections

Search

Start Over Subjects Multiple Myeloma -- drug therapy ✖Remove constraint Subjects: Multiple Myeloma -- drug therapy

1. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, January 2020
Subject(s):
Biomarkers
Clinical Trials as Topic
Drug Approval
Drug Development
Drugs, Investigational
Hematologic Neoplasms -- drug therapy
Investigational New Drug Application
Neoplasm, Residual
Endpoint Determination
Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Leukemia, Myeloid, Acute -- drug therapy
Leukemia, Promyelocytic, Acute -- drug therapy
Multiple Myeloma -- drug therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Prognosis
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

2. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report

Author(s):
Lee, Sei J., author
Beinfeld, Molly, author
Fluetsch, Noemi, author
Whittington, Melanie, D., author
Pearson, Steven D., author
Ollendorf, Daniel A., author
McQueen, R. Brett, author
Gutierrez, Eric, (Of University of Colorado Anschutz Medical Campus), author
Kwon, Sue, (Of University of Colorado Anschutz Medical Campus), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, November 22, 2022
Subject(s):
Immunoconjugates -- therapeutic use
Immunotherapy, Adoptive
Multiple Myeloma -- drug therapy
United States